it would seem that way, everything i can find has BTX1801 headed for "phase 1b/2". some other articles suggest it had leverage from the 1803 results. phase 1 being largely for safety and dosage, perhaps the these were confirmed by 1803 MOA, positioning BOT to trial the 'antimicrobial' application at ph2 directly.
Ann: Botanix Initiates BTX 1702 Rosacea Study, page-16
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $456.7M | |||
| Open | High | Low | Value | Volume |
| 29.5¢ | 30.5¢ | 29.0¢ | $1.147M | 3.861M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 589472 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 39319 | 2 |
View Market Depth
| Last trade - 16.10pm 03/06/2024 (20 minute delay) ? |
|
|||||
|
Last
29.0¢ |
Change
0.000 ( 1.13 %) |
||||
| Open | High | Low | Volume | ||
| 29.5¢ | 30.5¢ | 29.0¢ | 2638633 | ||
| Last updated 15.59pm 03/06/2024 ? | |||||
| BOT (ASX) Chart |